AstraZeneca Full year and Q4 2023 Financial Results

Strong growth and pipeline momentum with three new medicines approved since the third quarter

...

Related Keywords

United Kingdom ,Maryland ,United States ,Rockville ,Japan ,China ,Bio ,Pascal Soriot ,Astrazeneca ,Alliance Revenue For Astrazeneca ,Sustainable Markets Initiative Health Systems Task ,Icosavax Inc ,Alliance Revenue ,Gracell Biotechnologies Inc ,Total Revenue ,Product Sales ,Rare Disease ,Operating Margin ,Core Tax Rate ,Chief Executive Officer ,Priority Review ,Pulmicort Flexhaler ,Core Tax ,Investor Day ,Collaboration Revenue ,China Emerging ,Product Sales Gross Margin ,Core Rd To Total Revenue ,Increased Interest ,Clinical Trials Appendix ,Gracell Biotechnologies ,Envision Energy ,Full Year ,Factual Change ,Core Product Sales Gross Margin ,Gross Margin ,Bridgebio Pharma Inc ,Markets ,